15.1 Femoral Hemostasis Techniques: Manual Compression, Figure-of-8 & Closure Devices

15.1 Femoral Hemostasis Techniques: Manual Compression, Figure-of-8 & Closure Devices

Vascular access management is a critical determinant of patient safety and procedural success in the cardiac electrophysiology (EP) laboratory. Complex interventional procedures—such as catheter ablation for atrial fibrillation (AF), atypical flutter, and ventricular tachycardia (VT)—routinely require multiple venous cannulations (e.g., dual 8.5 Fr transseptal sheaths, 10–11 Fr intracardiac echocardiography [ICE] sheaths) and frequent arterial access for continuous hemodynamic blood pressure monitoring or retrograde left ventricular mapping. Concurrently, high-intensity systemic anticoagulation (intra-procedural unfractionated heparin titrated to target Activated Clotting Times [ACT] of 300 to 350+ seconds) is maintained throughout left-sided procedures to mitigate thromboembolic stroke.

Achieving rapid, durable hemostasis while preventing devastating access-site complications (such as pseudoaneurysm, arteriovenous fistula, and retroperitoneal hemorrhage) requires strict adherence to laboratory removal thresholds, precise anatomical hand positioning, and expert deployment of manual, mechanical, and bioresorbable closure technologies.

---

Vascular Access Sheath Removal Protocols

Laboratory Prerequisites & ACT Thresholds

Catheter access sheaths must never be removed indiscriminately following an interventional case. The biological integrity of the vascular repair process depends on the patient's real-time coagulation cascade status. The Activated Clotting Time (ACT) is the primary point-of-care laboratory test used to guide safe sheath withdrawal:

• Arterial Sheath Pull Threshold: Arterial sheaths require an ACT < 150 to 180 seconds prior to manual sheath removal. Because the common femoral artery is a high-pressure pulsatile vessel (mean arterial pressure 70–105 mmHg, systolic peak 120–160+ mmHg), attempting manual compression in a therapeutically heparinized patient (ACT > 200 seconds) dramatically increases the incidence of arterial re-bleeding, expanding groin hematomas, and pseudoaneurysms.
• Venous Sheath Pull Threshold: Venous sheaths operate under low-pressure, capacitance hemodynamics (central venous pressure 4–12 mmHg). Venous sheaths can safely undergo manual compression at an ACT < 250 to 280 seconds. Furthermore, when specialized closure techniques such as the figure-of-8 suture are utilized, venous sheaths can be pulled immediately post-procedure regardless of the ACT level (even with an ACT > 350 seconds), eliminating the delay required for systemic heparin clearance.

Protamine Sulfate Titration & Neutralization Mechanics

If arterial sheaths must be removed urgently, or if active access-site extravasation occurs in the presence of therapeutic heparinization, protamine sulfate is administered for rapid pharmacological reversal:

• Dosing Stoichiometry: Protamine is a strongly basic, positively charged polycationic protein derived from salmon sperm that binds electrostatically to strongly acidic, negatively charged unfractionated heparin molecules, forming an inert, stable salt without anticoagulant activity. Each 1.0 mg of protamine sulfate neutralizes approximately 100 USP units of unfractionated heparin.
• Pharmacokinetic Clearance Adjustment: Unfractionated heparin has an elimination half-life of 60 to 90 minutes. Consequently, the required protamine dose must be calculated based on the active circulating heparin remaining rather than the total cumulative procedural dose. For example, if 5,000 units of heparin were administered 60 minutes prior, approximately 2,500 units remain active, requiring only 25 mg of protamine.
• Infusion Rate & Ceiling Dose: The maximum single dose of protamine sulfate is 50 mg. Protamine must be administered as a slow IV infusion over 10 to 15 minutes (never as an undiluted rapid IV push).
• High-Risk Populations & Adverse Reactions:
  • Risk Cohorts: Patients with prior exposure to NPH insulin (neutral protamine Hagedorn), patients with severe fish or seafood allergies, and males who have undergone vasectomy (who produce anti-sperm antibodies that cross-react with protamine epitopes) are at high risk for severe hypersensitivity.
  • Hemodynamic Collapse: Rapid administration precipitates acute systemic histamine release causing refractory systemic vasodilation and profound hypotension. More catastrophically, protamine can trigger severe catastrophic pulmonary vasoconstriction mediated by thromboxane A2, manifesting as acute pulmonary arterial hypertension, bronchospasm, and sudden right ventricular failure.

---

Hemostasis Modalities

1. Manual Compression: Anatomical Principles & Execution

Manual compression remains the universal benchmark of vascular hemostasis against which all closure devices are compared.

               [Inguinal Ligament]
                       |
                       v
        (O)=========================(O)  <--- Common Femoral Artery (CFA)
                 |          |
                 |          +--- Arteriotomy Site (Over Bony Femoral Head)
                 |                   ^
                 |                   |  [Two-Finger Compression Zone]
                 |                   |  (1-2 cm Proximal to Skin Puncture)
                 |
                 +---------> Angle of Needle Entry (~45°)
                                     |
                                     v
                             [Skin Puncture Site]

• Anatomical Puncture Geometry: Because the access needle enters the skin at a 30° to 45° angle, the skin puncture site is located 1 to 2 cm distal (caudad) to the actual entry point into the vessel wall (the arteriotomy or venotomy). Applying pressure directly over the cutaneous puncture site leaves the intravascular hole uncompressed, allowing arterial blood to escape under high pressure into the deep subcutaneous space.
• Hand Positioning: The operator positions two or three fingertips (index, middle, and ring fingers) aligned longitudinally 1 to 2 cm proximal (cephalad) to the skin puncture site, directly over the vascular arteriotomy. The vessel must be compressed directly against the underlying bony anterior surface of the femoral head (which provides a rigid, flat backboard). Compressing above the femoral head allows blood to extravasate retroperitoneally; compressing below the femoral head compresses soft muscular tissue that cannot provide counter-resistance.
• Compression Duration & Protocol:
  • Arterial Access: Hold continuous, firm occlusive pressure for 15 to 20 minutes. Over the final 3 to 5 minutes, pressure is slowly and progressively tapered rather than abruptly released, allowing the fragile platelet plug and fibrin mesh to consolidate.
  • Venous Access: Hold continuous moderate pressure for 10 to 15 minutes.
  • Pulse Monitoring: The operator must maintain tactile palpation of the dorsalis pedis (DP) and posterior tibial (PT) pulses on the ipsilateral foot throughout arterial compression. Pressure should be sufficient to halt local extravasation while preserving distal arterial flow; completely obliterating distal perfusion for extended periods induces acute arterial thrombosis.
• Post-Compression Bed Rest Guidelines:
  • Arterial manual hold: Strict supine bed rest for 4 to 6 hours with the cannulated leg immobilized.
  • Venous manual hold: Strict supine bed rest for 2 to 3 hours.

2. Figure-of-8 (Z-Stitch) Suture Technique

The figure-of-8 suture (also known as the subcutaneous purse-string or Z-stitch) has revolutionized venous hemostasis in high-volume electrophysiology suites performing complex left atrial procedures.

• Clinical Rationale: Procedures such as AFib ablation or left atrial appendage occlusion require multiple large-bore sheaths (e.g., two 8.5 Fr steerable guiding sheaths and a 10–11 Fr ICE sheath) in the same femoral vein. Administering protamine to reverse heparin at the end of the case is undesirable in AF patients because early post-ablation thromboembolism can occur during acute atrial stunning. The figure-of-8 stitch bypasses the need for protamine.
• Surgical Technique: Using a heavy, non-absorbable braided suture (e.g., 0 or 2-0 silk on a curved cutting needle):
  1. The needle passes subcutaneously through the skin approximately 1 cm inferior to the venous entry tract, traverses the subcutaneous tissue beneath the sheaths, and exits on the opposite side.
  2. The suture is crossed over the top of the sheaths in a figure-of-8 configuration and passed through the skin and subcutaneous tissue 1 cm superior to the entry tract.
  3. While the primary operator withdraws the venous sheaths simultaneously under gentle aspiration, the assistant cinches the suture firmly and ties a surgical knot.
• Mechanics of Action: The suture does not penetrate the venous wall; rather, it firmly compresses the surrounding subcutaneous fascia and perivascular tissue down against the venotomy tract, creating instant mechanical tamponade.
• Key Advantages & Protocol: Hemostasis is achieved in < 1 minute, regardless of whether the ACT is 350 or 400 seconds. No protamine is required. The suture is left in place while the patient remains on bed rest (typically 2 to 4 hours) and is clipped and removed prior to ambulation or hospital discharge after verifying site stability.

3. Vascular Closure Devices (VCDs)

Vascular closure devices provide rapid, mechanical arteriotomy sealing, substantially shortening bed rest and improving patient comfort.

Suture-Mediated Closure (Perclose ProGlide)

• Mechanism: Deploys two needles through the arterial wall from the inside out, delivering a pre-tied monofilament polypropylene suture that directly apposes the edges of the arteriotomy.
• Step-by-Step Deployment:
  1. The device is advanced over a 0.038-inch guidewire into the femoral artery.
  2. Pulsatile blood flow exits the designated marker lumen, confirming that the footplate is inside the arterial lumen.
  3. The footplate is deployed (lever lifted to 90°), and gentle upward traction is applied until tactile resistance is felt against the anterior arterial wall, halting the marker bleed.
  4. The plunger is compressed, driving two needles through the adventitia, media, and intima into the footplate cuffs.
  5. The footplate is retracted, and the device is withdrawn over the wire, pulling the suture needles out through the skin tract.
  6. A dedicated knot pusher (Snare / Deluxe QuickCut) is advanced down the suture rail to cinch the sliding pre-tied knot down snugly onto the exterior adventitial wall of the arteriotomy while maintaining wire access.
  7. Once hemostasis is verified, the wire is removed, final locking force is applied, and the suture is cut flush with the skin.
• Large-Bore Pre-Closure Technique: For sheaths > 8 Fr (up to 21–24 Fr in percutaneous ventricular assist devices or large-bore structural cases), the "pre-close" technique involves deploying two ProGlide devices at 10 o'clock and 2 o'clock orientations at the start of the case before large sheath introduction.

Anchor-and-Collagen Plug Devices (Angio-Seal)

• Mechanism: Creates a mechanical "sandwich" seal across the arteriotomy consisting of three bioresorbable components:
  1. A flat, elongated polyglycolic/polylactic acid intravascular anchor.
  2. A purified bovine collagen sponge positioned extravascularly on the arterial surface.
  3. A self-cinching bioresorbable suture connecting the anchor and collagen plug.
• Deployment: The insertion sheath is advanced over a guidewire until the drip hole flashes pulsatile blood. The carrier assembly is inserted, locking into the sheath. The anchor is deployed inside the lumen by pulling back the carrier. Gentle upward traction seats the anchor flat against the endocardial arteriotomy. The tamper tube is slid down, compacting the collagen plug firmly against the adventitial surface. The anchor and collagen degrade completely via enzymatic hydrolysis over 60 to 90 days.

Extravascular Sealant Devices (Mynx)

• Mechanism: Employs a freeze-dried polyethylene glycol (PEG) hydrogel sealant deployed entirely extravascularly in the tissue tract directly over the arteriotomy. An intravascular balloon provides temporary counter-traction during deployment and is subsequently deflated and removed. Because no foreign hardware remains inside the vessel lumen, there is zero risk of intravascular anchor embolization. The PEG sealant resorbs completely within 30 days.

Contraindications to Vascular Closure Devices

VCDs carry catastrophic risks if deployed inappropriately. Strict contraindications include:

• High Puncture (Above the Inguinal Ligament): Puncture into the external iliac artery precludes compression; footplate seating against an uncompressible vessel risks fatal retroperitoneal bleeding.
• Low Puncture (Below Common Femoral Bifurcation): Puncturing the superficial femoral artery (SFA) or profunda femoris artery risks deploying anchors into small-caliber branches, causing acute arterial thrombosis, vessel dissection, or leg ischemia.
• Vessel Diameter < 5 mm: High risk of mechanical luminal obstruction.
• Severe Peripheral Vascular Disease (PVD) / Dense Calcification: Heavy anterior wall plaque prevents anchor seating, shears sutures, or fractures brittle calcified arterial walls.
• Active Systemic Infection / Bacteremia: Bioresorbable foreign bodies serve as a nidus for severe endovascular graft or arteriotomy infections.

4. Mechanical Compression Devices

Mechanical clamps provide automated downward pressure, sparing staff fatigue during prolonged holds:

• FemoStop System: Comprises an adjustable rigid plastic arch secured around the patient's pelvis and a sterile, disposable pneumatic transparent dome positioned over the arteriotomy.
  • Calibration Protocol: The dome is inflated with an attached manometer to 10 to 20 mmHg above the patient's baseline systolic blood pressure for the initial 1 to 2 minutes to establish acute hemostasis as the sheath is withdrawn. Pressure is rapidly bled down to the systolic blood pressure level for 10 to 15 minutes, and then titrated down to systolic minus 10 to 20 mmHg for the duration of the hold (typically 30–60 minutes), ending with an observation period at 30 mmHg.
• C-Clamp Device: A mechanical steel arm with an adjustable screw and disposable plastic compression disc. Counter-force is applied directly downward onto the femoral head.
• Complications & Safety Warnings:
  • Skin Pressure Necrosis: Static high-pressure compression obliterates cutaneous microcirculation, causing blistering and full-thickness skin sloughing.
  • Femoral Nerve Neuropathy: Excessive compression of the neurovascular bundle lateral to the femoral artery produces ischemic compression of the femoral nerve, manifesting as acute quadriceps weakness, knee buckling upon ambulation, anterior thigh numbness, and loss of the patellar tendon reflex.
  • Vasovagal Reactions: Intense local pressure triggers severe vagal reflexes (severe bradycardia and hypotension) requiring immediate pressure relief and IV atropine.

Comparison of Femoral Hemostasis Modalities